Medical countermeasures against nuclear threats: Radionuclide decorporation agents

David R. Cassatt, Joseph Michael Kaminski, Richard J. Hatchett, Andrea L. DiCarlo, Jessica M. Benjamin, Bert W. Maidment

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Exposure to radionuclides disseminated by a radiological dispersion device or deposited as fallout after a nuclear power plant accident or detonation of an improvised nuclear device could result in internal contamination of a significant number of individuals. Internalized radionuclides may cause both acute and chronic radiation injury and increase an individual's risk of developing cancer. This damage and risk can be mitigated by the use of decorporation agents that reduce internal contamination. Unfortunately, most effective agents decorporate only a limited range of radionuclides, and some are formulated in ways that would make administration in mass casualty situations challenging. There is a need for new radionuclide decorporation agents, reformulations of existing agents, and/or expansion of the labeled indications for existing treatments. Researchers developing novel or improved decorporation agents should also understand the regulatory pathway for these products. This workshop, the first in nearly half a century to focus exclusively on radionuclide decorporation, brought together researchers and scientific administrators from academia, government and industry as well as senior regulatory affairs officers and U.S. Food and Drug Administration personnel. Meeting participants reviewed recent progress in the development of decorporation agents and contemplated the future of the field.

Original languageEnglish (US)
Pages (from-to)540-548
Number of pages9
JournalRadiation research
Volume170
Issue number4
DOIs
StatePublished - Oct 1 2008

Fingerprint

countermeasures
Radioisotopes
radioactive isotopes
Research Personnel
Mass Casualty Incidents
nuclear devices
Nuclear Power Plants
contamination
Equipment and Supplies
Radiation Injuries
casualties
radiation injuries
United States Food and Drug Administration
Administrative Personnel
fallout
nuclear power plants
Accidents
personnel
accidents
detonation

ASJC Scopus subject areas

  • Biophysics
  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

Cassatt, D. R., Kaminski, J. M., Hatchett, R. J., DiCarlo, A. L., Benjamin, J. M., & Maidment, B. W. (2008). Medical countermeasures against nuclear threats: Radionuclide decorporation agents. Radiation research, 170(4), 540-548. https://doi.org/10.1667/RR1485.1

Medical countermeasures against nuclear threats : Radionuclide decorporation agents. / Cassatt, David R.; Kaminski, Joseph Michael; Hatchett, Richard J.; DiCarlo, Andrea L.; Benjamin, Jessica M.; Maidment, Bert W.

In: Radiation research, Vol. 170, No. 4, 01.10.2008, p. 540-548.

Research output: Contribution to journalArticle

Cassatt, DR, Kaminski, JM, Hatchett, RJ, DiCarlo, AL, Benjamin, JM & Maidment, BW 2008, 'Medical countermeasures against nuclear threats: Radionuclide decorporation agents', Radiation research, vol. 170, no. 4, pp. 540-548. https://doi.org/10.1667/RR1485.1
Cassatt DR, Kaminski JM, Hatchett RJ, DiCarlo AL, Benjamin JM, Maidment BW. Medical countermeasures against nuclear threats: Radionuclide decorporation agents. Radiation research. 2008 Oct 1;170(4):540-548. https://doi.org/10.1667/RR1485.1
Cassatt, David R. ; Kaminski, Joseph Michael ; Hatchett, Richard J. ; DiCarlo, Andrea L. ; Benjamin, Jessica M. ; Maidment, Bert W. / Medical countermeasures against nuclear threats : Radionuclide decorporation agents. In: Radiation research. 2008 ; Vol. 170, No. 4. pp. 540-548.
@article{a25b7ab3b185424ca3c4559d936a26c1,
title = "Medical countermeasures against nuclear threats: Radionuclide decorporation agents",
abstract = "Exposure to radionuclides disseminated by a radiological dispersion device or deposited as fallout after a nuclear power plant accident or detonation of an improvised nuclear device could result in internal contamination of a significant number of individuals. Internalized radionuclides may cause both acute and chronic radiation injury and increase an individual's risk of developing cancer. This damage and risk can be mitigated by the use of decorporation agents that reduce internal contamination. Unfortunately, most effective agents decorporate only a limited range of radionuclides, and some are formulated in ways that would make administration in mass casualty situations challenging. There is a need for new radionuclide decorporation agents, reformulations of existing agents, and/or expansion of the labeled indications for existing treatments. Researchers developing novel or improved decorporation agents should also understand the regulatory pathway for these products. This workshop, the first in nearly half a century to focus exclusively on radionuclide decorporation, brought together researchers and scientific administrators from academia, government and industry as well as senior regulatory affairs officers and U.S. Food and Drug Administration personnel. Meeting participants reviewed recent progress in the development of decorporation agents and contemplated the future of the field.",
author = "Cassatt, {David R.} and Kaminski, {Joseph Michael} and Hatchett, {Richard J.} and DiCarlo, {Andrea L.} and Benjamin, {Jessica M.} and Maidment, {Bert W.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1667/RR1485.1",
language = "English (US)",
volume = "170",
pages = "540--548",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "Radiation Research Society",
number = "4",

}

TY - JOUR

T1 - Medical countermeasures against nuclear threats

T2 - Radionuclide decorporation agents

AU - Cassatt, David R.

AU - Kaminski, Joseph Michael

AU - Hatchett, Richard J.

AU - DiCarlo, Andrea L.

AU - Benjamin, Jessica M.

AU - Maidment, Bert W.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Exposure to radionuclides disseminated by a radiological dispersion device or deposited as fallout after a nuclear power plant accident or detonation of an improvised nuclear device could result in internal contamination of a significant number of individuals. Internalized radionuclides may cause both acute and chronic radiation injury and increase an individual's risk of developing cancer. This damage and risk can be mitigated by the use of decorporation agents that reduce internal contamination. Unfortunately, most effective agents decorporate only a limited range of radionuclides, and some are formulated in ways that would make administration in mass casualty situations challenging. There is a need for new radionuclide decorporation agents, reformulations of existing agents, and/or expansion of the labeled indications for existing treatments. Researchers developing novel or improved decorporation agents should also understand the regulatory pathway for these products. This workshop, the first in nearly half a century to focus exclusively on radionuclide decorporation, brought together researchers and scientific administrators from academia, government and industry as well as senior regulatory affairs officers and U.S. Food and Drug Administration personnel. Meeting participants reviewed recent progress in the development of decorporation agents and contemplated the future of the field.

AB - Exposure to radionuclides disseminated by a radiological dispersion device or deposited as fallout after a nuclear power plant accident or detonation of an improvised nuclear device could result in internal contamination of a significant number of individuals. Internalized radionuclides may cause both acute and chronic radiation injury and increase an individual's risk of developing cancer. This damage and risk can be mitigated by the use of decorporation agents that reduce internal contamination. Unfortunately, most effective agents decorporate only a limited range of radionuclides, and some are formulated in ways that would make administration in mass casualty situations challenging. There is a need for new radionuclide decorporation agents, reformulations of existing agents, and/or expansion of the labeled indications for existing treatments. Researchers developing novel or improved decorporation agents should also understand the regulatory pathway for these products. This workshop, the first in nearly half a century to focus exclusively on radionuclide decorporation, brought together researchers and scientific administrators from academia, government and industry as well as senior regulatory affairs officers and U.S. Food and Drug Administration personnel. Meeting participants reviewed recent progress in the development of decorporation agents and contemplated the future of the field.

UR - http://www.scopus.com/inward/record.url?scp=55349084049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55349084049&partnerID=8YFLogxK

U2 - 10.1667/RR1485.1

DO - 10.1667/RR1485.1

M3 - Article

C2 - 19024661

AN - SCOPUS:55349084049

VL - 170

SP - 540

EP - 548

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 4

ER -